Video

Phase II AMG 386 and Paclitaxel Combination Trial

Author(s):

Beth Y. Karlan MD

Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

Beth Y. Karlan MD Director at Cedars-Sinai Women's Cancer Research Institute Provides an Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

Related Videos
Rohan Garje, MD
Manmeet Ahluwalia, MD, MBA, FASCO
Jakub Svoboda, MD
Suneel Kamath, MD
Ranee Mehra, MD
Jonathan Strosberg, MD
VK Gadi, MD, PhD
Komal Jhaveri, MD, FACP
Mark Pegram, MD
David R. Spigel, MD, chief scientific officer, Sarah Cannon Research Institute
Related Content
Mansoor Raza Mirza, MD
June 7th 2024

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Frederik Marmé, MD, PhD, of the University of Heidelberg
June 2nd 2024

Addition of Atezolizumab to Chemotherapy and Bevacizumab Does Not Yield Benefit in Ovarian Cancer

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Jean-Marc Classe, MD, PhD
June 2nd 2024

Lymphadenectomy Fails to Boost Survival in Advanced Ovarian Cancer

Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology